United Therapeutics CEO Martine Rothblatt Sells $1.06 Million in Stock

Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics, sold 1,920 shares of company stock on September 30, 2026, for a total value of approximately $1.06 million. The transaction was conducted under a pre-arranged trading plan, which is a standard regulatory mechanism used by corporate executives to manage equity holdings.

"The sale was executed under a 10b5-1 trading plan adopted on November 7, 2025," according to a report on the transaction.

Understanding 10b5-1 Trading Plans

A 10b5-1 trading plan is a legal mechanism that allows corporate insiders to establish a pre-determined schedule for selling company stock. By setting these parameters in advance, executives can sell shares at specific times or prices without triggering concerns regarding insider trading. The plan is adopted when the executive is not in possession of material non-public information, and it serves as an affirmative defense against allegations that the trades were based on confidential corporate developments.

Context of the Current Sale

The plan governing Rothblatt's recent sale was established in November 2025. Regulatory disclosures indicate this specific arrangement remains in effect until the earlier of two milestones:

• December 31, 2026
• The exercise of 1,734,410 stock options scheduled to expire on March 15, 2027

These disclosures provide visibility into the executive's equity management strategy. They distinguish these routine sales from discretionary transactions that might otherwise be interpreted as reactions to current company performance or market conditions.